Phase 1/2 × Interventional × Immunoglobulin Light-chain Amyloidosis × Clear all ALACRITY
Phase 1/2 Recruiting
91 enrolled
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Phase 1/2 Recruiting
49 enrolled
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
Phase 1/2 Recruiting
37 enrolled
NEXICART-2
Phase 1/2 Recruiting
40 enrolled
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Phase 1/2 Recruiting
53 enrolled
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Phase 1/2 Terminated
32 enrolled
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
Phase 1/2 Withdrawn
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
Phase 1/2 Completed
18 enrolled
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
Phase 1/2 Completed
28 enrolled
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
Phase 1/2 Completed
57 enrolled
Daratumumab for the Treatment of Patients With AL Amyloidosis
Phase 1/2 Completed
22 enrolled 10 charts
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
Phase 1/2 Completed
37 enrolled
CATALYST
Phase 1/2 Completed
10 enrolled 14 charts
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
Phase 1/2 Completed
27 enrolled 14 charts
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
Phase 1/2 Completed
21 enrolled
Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Phase 1/2 Completed
69 enrolled
Bu Flu TBI
Phase 1/2 Completed
147 enrolled 19 charts
Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction
Phase 1/2 Completed
10 enrolled 4 charts
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
Phase 1/2 Completed
30 enrolled
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
Phase 1/2 Completed
47 enrolled
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies
Phase 1/2 Withdrawn
Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis
Phase 1/2 Completed
27 enrolled
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
Phase 1/2 Completed